These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37400631)

  • 1. Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma.
    Teo WZY; Ong IYE; Tong JWY; Ong WL; Lin A; Song F; Tai BC; Ooi M; Seokojo CY; Chen Y; Nagarajan C; Chng WJ; de Mel S
    Curr Hematol Malig Rep; 2023 Oct; 18(5):190-200. PubMed ID: 37400631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Myeloma Minimal Residual Disease.
    Paiva B; García-Sanz R; San Miguel JF
    Cancer Treat Res; 2016; 169():103-122. PubMed ID: 27696260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease analysis in myeloma - when, why and where.
    Yanamandra U; Kumar SK
    Leuk Lymphoma; 2018 Aug; 59(8):1772-1784. PubMed ID: 29019452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What to do with minimal residual disease testing in myeloma.
    Manasanch EE
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
    Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
    BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
    Munshi NC; Avet-Loiseau H; Rawstron AC; Owen RG; Child JA; Thakurta A; Sherrington P; Samur MK; Georgieva A; Anderson KC; Gregory WM
    JAMA Oncol; 2017 Jan; 3(1):28-35. PubMed ID: 27632282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
    Martinez-Lopez J; Alonso R; Wong SW; Rios R; Shah N; Ruiz-Heredia Y; Sanchez-Pina JM; Sanchez R; Bahri N; Zamanillo I; Poza M; Buenache N; Encinas C; Juarez L; Miras F; Collado L; Barrio S; Martin T; Cedena MT; Wolf J
    J Hematol Oncol; 2021 Aug; 14(1):126. PubMed ID: 34404440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.
    Ferla V; Antonini E; Perini T; Farina F; Masottini S; Malato S; Marktel S; Lupo Stanghellini MT; Tresoldi C; Ciceri F; Marcatti M
    Front Oncol; 2022; 12():932852. PubMed ID: 36052251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment.
    Landgren O; Lu SX; Hultcrantz M
    Semin Hematol; 2018 Jan; 55(1):44-50. PubMed ID: 29759154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep Response in Multiple Myeloma: A Critical Review.
    Fulciniti M; Munshi NC; Martinez-Lopez J
    Biomed Res Int; 2015; 2015():832049. PubMed ID: 26783530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
    Cavo M; San-Miguel J; Usmani SZ; Weisel K; Dimopoulos MA; Avet-Loiseau H; Paiva B; Bahlis NJ; Plesner T; Hungria V; Moreau P; Mateos MV; Perrot A; Iida S; Facon T; Kumar S; van de Donk NWCJ; Sonneveld P; Spencer A; Krevvata M; Heuck C; Wang J; Ukropec J; Kobos R; Sun S; Qi M; Munshi N
    Blood; 2022 Feb; 139(6):835-844. PubMed ID: 34289038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
    Diamond B; Korde N; Lesokhin AM; Smith EL; Shah U; Mailankody S; Hultcrantz M; Hassoun H; Lu SX; Tan C; Rustad EH; Maura F; Maclachlan K; Peterson T; Derkach A; Devlin S; Landau HJ; Scordo M; Chung DJ; Shah GL; Lahoud O; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Giralt SA; Landgren O
    Lancet Haematol; 2021 Jun; 8(6):e422-e432. PubMed ID: 34048681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
    Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
    Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
    Perrot A; Lauwers-Cances V; Corre J; Robillard N; Hulin C; Chretien ML; Dejoie T; Maheo S; Stoppa AM; Pegourie B; Karlin L; Garderet L; Arnulf B; Doyen C; Meuleman N; Royer B; Eveillard JR; Benboubker L; Dib M; Decaux O; Jaccard A; Belhadj K; Brechignac S; Kolb B; Fohrer C; Mohty M; Macro M; Richardson PG; Carlton V; Moorhead M; Willis T; Faham M; Anderson KC; Harousseau JL; Leleu X; Facon T; Moreau P; Attal M; Avet-Loiseau H; Munshi N
    Blood; 2018 Dec; 132(23):2456-2464. PubMed ID: 30249784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New criteria for response assessment: role of minimal residual disease in multiple myeloma.
    Paiva B; van Dongen JJ; Orfao A
    Blood; 2015 May; 125(20):3059-68. PubMed ID: 25838346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?
    Paiva B; Puig N; García-Sanz R; San Miguel JF;
    Clin Cancer Res; 2015 May; 21(9):2001-8. PubMed ID: 25754350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.
    Landgren O; Devlin S; Boulad M; Mailankody S
    Bone Marrow Transplant; 2016 Dec; 51(12):1565-1568. PubMed ID: 27595280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.
    Landgren O; Owen RG
    Cytometry B Clin Cytom; 2016 Jan; 90(1):14-20. PubMed ID: 26147584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.
    Landgren O; Rajkumar SV
    Clin Cancer Res; 2016 Nov; 22(22):5428-5433. PubMed ID: 28151710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.